Market Report Source

Overview

The medical imaging segments are poised for a major new phase of growth fueled by the availability of new technology coming out of the computer and digital information technology segment. Continuous improvements in technology are resulting in a growing number of new imaging tests that combine high levels of accuracy with rapid, easy-to-use product formats. Part of that medical imaging improvement is coming from positron emission tomography (PET). PET is a scanning technique used in combination with small amounts of radio-labeled compounds to visualize the anatomy and function of the brain.

The purpose of this TriMark Publications report is to describe the specific market segment of the diagnostics medical imaging market called PET scanning. This sector includes all of the generally accepted imaging activities that are currently used in PET, including equipment for PET, PET/CT, SPECT and the use of radiopharmaceuticals for imaging. It examines these clinical measurement devices and their reagents and supplies as used in hospitals and clinics. It also reviews associated clinical market segments in which PET scanning has taken a prominent role including cancer treatment, cardiology, and neurology imaging markets.

Table of Contents

1 Overview 4
1.1 Statement of Report 4
1.2 Scope of this Report 4
1.3 Methodology 5
1.4 Executive Summary 6

2 Overview of the Medical Imaging Market 8
2.1 Medical Imaging Industry Market Size 8
2.2 Medical Imaging Infrastructure 9
2.2.1 Total Healthcare Expenditures and Demographics 9
2.2.2 Number of Hospitals 11
2.2.3 Number of Radiologists 12
2.2.4 Radiologic Services 13
2.2.5 Medical Imaging Companies 15
2.2.6 Medical Imaging Market Drivers 16
2.2.7 Market Restraints 17
2.2.8 Market Segments for PET Imaging 18
2.2.9 Key Players in the PET Imaging Segment 22
2.2.10 Medical Imaging Sector Analysis 24
2.3 Structure and Use of PET Imaging 25
2.3.1 Functional Imaging versus Anatomic Imaging 25
2.3.2 Functional Imaging Using Single-Photon Imaging (SPECT) 26
2.3.3 PET in Clinical Use 29
2.3.4 PET Sensitivity 30
2.3.5 Therapeutic Uses of PET 30
2.3.6 PET/CT 30
2.3.7 The Future of PET in Cancer Imaging 31
2.3.8 PET Reimbursement 31
2.4 Radiopharmaceutical Imaging 32
2.4.1 Cardinal Health Acquires PET Radiopharmaceutical Production Facilities 33
2.4.2 GE Healthcare Launches New Platform for Automated Synthesis of PET Radiopharmaceuticals 33
2.4.3 Siemens Medical PETNET Radiopharmacy 34
2.4.4 Future Growth of PET Imaging Procedures 34
2.4.5 Diagnostic Radiopharmaceuticals: Market Analysis and Future Prospects 34
2.4.6 New Radiopharmaceutical Applications 35

3 PET Market 37
3.1 Market Size 37
3.2 Total PET and PET/CT Market Trends 37
3.2.1 Market Segmentation and Definitions 38
3.2.2 Overview 38
3.2.3 Market Measurements 39
3.2.4 Market Drivers 40
3.2.5 Market Restraints 41
3.2.6 Future Needs for Market Development 42
3.2.7 Clinical Usages 42
3.3 Total PET and PET/CT Market Forecasts 43
3.3.1 Revenue Forecasts 44
3.3.2 Unit Shipment Forecasts 45
3.3.3 Procedure Forecast 46
3.3.4 Competitive Structure 47
3.3.5 Market Share Analysis 49
3.3.6 Future Directions for PET 51
3.3.7 New PET Technology Platforms 52
3.4 SPECT Market Forecasts 53
3.5 Stand-Alone PET Market Forecasts 53
3.5.1 Revenue Forecasts 54
3.5.2 Unit Shipment Forecasts 54
3.5.3 Market Share Analysis 54
3.6 PET/CT Market Forecasts 54
3.6.1 PET/CT Revenue Forecasts 55
3.6.2 PET/CT Unit Shipment Forecasts 55
3.6.3 PET/CT Market Share Analysis 55
3.7 Products 56
3.7.1 Gamma Medica 56
3.7.2 Mallinckrodt 56
3.7.3 Naviscan PET Systems 56
3.7.4 Siemens Medical 56
3.7.5 TeraRecon 56
3.7.6 Toshiba America Medical Systems 56
3.7.7 CTI Molecular Imaging Inc. 56
3.7.8 GE Healthcare 57
3.7.9 Philips Medical Systems 57
3.7.10 MedImage Inc. 57

4 PET/CT 58
4.1 Strengths of CT and PET Scanning 58
4.2 Combining CT’s Strengths with PET Scanning 58
4.3 Nuclear Medicine Safety Protocols 59
4.4 PET Safety Protocols 60
4.4.1 Radiation Safety 61
4.4.2 Appropriate Shielding 62
4.4.3 Radioactive Package Protocols 63
4.5 Regulatory Requirements 64
4.6 PET and SPECT Tracers 65
4.6.1 FDG Centers 65
4.7 PET Imaging 66
4.8 PET and Cancer Staging 67
4.9 PET/CT Reimbursement 67

5 Hybrid Technology: PET/CT and SPECT/CT 69
5.1 PET/CT 69
5.2 SPECT/CT 69
5.2.1 Blending of Technology Platforms 70
5.2.2 SPECT vs. PET 70

6 SPECT and SPECT/CT 73
6.1 Single-Photon Emission Computed Tomography (SPECT) 73
6.1.1 SPECT Imaging 73
6.2 SPECT/CT 74
6.3 Potential Applications of SPECT/CT 74
6.4 New Technology Platforms: SPECT 77

7 Clinical PET/CT for Oncology Applications 78
7.1 Pulmonary Nodules 78
7.2 Non-Small-Cell Lung Cancer 78
7.3 Melanoma 79
7.4 Lymphoma 79
7.5 Colorectal Cancer 80
7.6 Head and Neck Cancer 81
7.7 Esophageal Cancer 81
7.8 Breast Cancer 81
7.9 Brain Cancer 82
7.10 Prostate Cancer 83
7.11 Ovarian Cancer 83
7.12 Cervical Cancer 83
7.13 Testicular Cancer 84
7.14 Thyroid Cancer 84
7.15 Pancreatic Cancer 84
7.16 Trends in Clinical Use of PET/CT 84
7.17 Development of PET/MRI 84

8 Company Listings 86

Appendix 1. Radiopharmaceutical Diagnostic Imaging Agent Codes and PET Scan Services 88

LIST OF TABLES
Table 2.1: U.S. Medical Imaging Market Size, 2001 to 2010 9
Table 2.2: Global Medical Imaging Market Size, 2001 to 2010 9
Table 2.3: U.S. Healthcare Expenditures, 1999 to 2010 10
Table 2.4: U.S. Health Expenditures as a Percentage of GDP, 1999 to 2010 10
Table 2.5: U.S. User Expenditures for Medical Imaging Equipment and Related Products 10
Table 3.1: Type of Imaging Offered by Facility 37
Table 3.2: PET Procedures by Type 39
Table 3.3: PET Patient Studies Performed in U.S. 43
Table 3.4: Worldwide Dollar Sales of PET Imaging Systems, 2004 to 2011 44
Table 3.5: U.S. Dollar Sales of PET Imaging Systems, 2004 to 2011 44
Table 3.6: Average Selling Price for PET, U.S. and Worldwide, 2004 to 2011 45
Table 3.7: Unit Sales of PET Imaging Systems, U.S. and Worldwide, 2004 to 2011 45
Table 3.8: Installed Base of PET Imaging Systems, U.S., 2004 to 2011 46
Table 3.9: PET Procedure Volume, 2004 to 2011 46
Table 3.10: FDG Sales, 2004 to 2011 47
Table 3.11: SPECT Procedure Volume, 2004 to 2011 53
Table 3.12: U.S. SPECT Scanner Market Size and Growth, 2002 to 2010 53
Table 3.13: U.S. Stand-Alone PET Scanner Market Size and Growth, 2004 to 2011 54
Table 3.14: U.S. PET/CT Scanner Market Size and Growth, 2002 to 2010 55
Table 4.1: PET Applications Approved for Reimbursement by CMS 68
Table 5.1: SPECT and PET Hybrid Sales Percentages 70